drugset
drugset / Trial / NCT00520169

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

NCT00520169 ↗

Phase 1 Completed 32 enrolled Javelin Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, single-center study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

Timeline

Start
2007-07
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 30 mg Intranasal

Indications

No indication recorded.